@misc{Borek_Ewelina_Pharmacoeconomic_2017,
 author={Borek, Ewelina},
 address={Kraków},
 howpublished={online},
 year={2017},
 school={Wydział Farmaceutyczny},
 language={pol},
 abstract={The aim of the work was to compare the cost-effectiveness of different chemotherapy schemes used in the second line chemotherapy of advanced cell lung cancer. Due to a therapeutic differences in case of the non small cel lung cancer alternative chemotherapies based on pemetrexed (PEME) and erlotinib (ERLO) were compared to docetaxel (DOC) based chemotherapy, in case of small cel lung cancer two schemes were compared: topotecan (TOPO) and cyclofosphamid-doxorubicin-vincristin (CAV). Medical records were collected retrospectively at the Katowice Oncology Center in Katowice. The patients were treated with one of the analyzed regimens between 2004 and 2012. The analysis was conducted from the perspective of the hospital. Only direct medical costs were analyzed. The cost-effectiveness of NSCLC and SCLC treatment was expressed in terms of incremental cost per additional life-year gained. Survival time was measured from the moment a patient started their second-line chemotherapy. An incremental and one-way sensitivity analyses were performed. The average cost per patient was 7350,86 PLN; 42199,52 PLN; 72695,89 PLN in the DOC, PEME and ERLO group respectively. In the SCLC group the average cost per patient were 5043,29 PLN in CAV and 9742,03 in TOPO. The average survival time from diagnosis to death of NSCLC patients treated with DOC, PEME and ERLO treatment regimen was 22,24; 21,89 an},
 abstract={d 28,09 months, respectively. In the SCLC the average patient survived 16,17 and 17,18 months from diagnosis, in CAV and TOPO, respectively. Second-line treatment for NSCLC is more cost-effective with docetaxel than with other treatment regimen. High prices of erlotinib, pemetrexed and topotecan and small differences in life expectancy increased the cost effectiveness ratio and made new type of treatment less cost-effective than standard therapy. Considering the differences in the prices of medicines and different finance systems of the health care in Poland and other countries in the world it is useful to carry out the pharmacoeconomic analyses.},
 title={Pharmacoeconomic analysis of second-line chemotherapy in patients with lung cancer},
 type={Praca doktorska},
 keywords={docetaksel, cost-effectiveness analysis, non small cell lung cancer, topotecan, small cell lung cancer},
}